Wall Street Zen Upgrades Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to “Strong-Buy”

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also issued reports on FMS. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has an average rating of “Reduce” and a consensus target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.1%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $23.51 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The company has a fifty day simple moving average of $24.67 and a 200-day simple moving average of $25.75. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $22.05 and a 12-month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The firm had revenue of $5.73 billion during the quarter, compared to analysts’ expectations of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in FMS. TD Waterhouse Canada Inc. purchased a new position in Fresenius Medical Care AG & Co. KGaA during the second quarter worth about $36,000. Brooklyn Investment Group boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 424.5% in the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock valued at $32,000 after purchasing an additional 1,040 shares in the last quarter. CIBC Private Wealth Group LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the period. Atlantic Union Bankshares Corp purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 2nd quarter worth approximately $43,000. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after buying an additional 1,768 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.